College of Integrative Medicine, Hebei University of Chinese Medicine, Hebei, China.
Hebei Yiling Pharmaceutical Research Institute, Hebei, China.
Pharm Biol. 2022 Dec;60(1):274-281. doi: 10.1080/13880209.2022.2029501.
Jinlida (JLD) as a traditional Chinese medicine formula has been used to treat type 2 diabetes mellitus (T2DM) and studies have shown its anti-obesity effect.
To investigate the therapeutic effects of JLD in a mouse model of non-alcoholic fatty liver (NAFL).
C57BL/6J mice were divided into three groups and fed a low-diet diet (LFD), high-fat diet (HFD), or HFD + JLD (3.8 g/kg) for 16 weeks, respectively. The free fatty acids-induced lipotoxicity in HepG2 cells were used to evaluate the anti-pyroptotic effects of JLD. The pharmacological effects of JLD on NAFL were investigated by pathological examination, intraperitoneal glucose and insulin tolerance tests, western blotting, and quantitative real-time PCR.
studies showed that JLD ameliorated HFD-induced liver injury, significantly decreased body weight and enhanced insulin sensitivity and improved glucose tolerance. Furthermore, JLD suppressed both the mRNA expression of caspase-1 (1.58 vs. 2.90), IL-1β (0.93 vs. 3.44) and IL-18 (1.34 vs. 1.60) and protein expression of NLRP3 (2.04 vs. 5.71), pro-caspase-1 (2.68 vs. 4.92) and IL-1β (1.61 vs. 2.60). , JLD inhibited the formation of lipid droplets induced by 2 mM FFA (IC = 2.727 mM), reduced the protein expression of NLRP3 (0.74 vs. 2.27), caspase-1 (0.57 vs. 2.68), p20 (1.67 vs. 3.33), and IL-1β (1.44 vs. 2.41), and lowered the ratio of -IKB-α/IKB-α (0.47 vs. 2.19).
JLD has a protective effect against NAFLD, which may be related to its anti-pyroptosis, suggesting that JLD has the potential as a novel agent in the treatment of NAFLD.
金利达（JLD）作为一种中药方剂，已被用于治疗 2 型糖尿病（T2DM），研究表明其具有抗肥胖作用。
探讨 JLD 在非酒精性脂肪性肝病（NAFL）小鼠模型中的治疗效果。
将 C57BL/6J 小鼠分为三组，分别给予低饮食（LFD）、高脂肪饮食（HFD）或 HFD+JLD（3.8g/kg）喂养 16 周。采用游离脂肪酸诱导的 HepG2 细胞脂毒性来评价 JLD 的抗细胞焦亡作用。通过病理检查、腹腔内葡萄糖和胰岛素耐量试验、western blot 和实时定量 PCR 研究 JLD 对 NAFL 的药理作用。
研究表明，JLD 改善了 HFD 诱导的肝损伤，显著降低了体重，增强了胰岛素敏感性，改善了葡萄糖耐量。此外，JLD 抑制了 caspase-1（1.58 对 2.90）、IL-1β（0.93 对 3.44）和 IL-18（1.34 对 1.60）的 mRNA 表达，以及 NLRP3（2.04 对 5.71）、前半胱天冬酶-1（2.68 对 4.92）和 IL-1β（1.61 对 2.60）的蛋白表达。JLD 抑制了 2mM FFA 诱导的脂滴形成（IC=2.727mM），降低了 NLRP3（0.74 对 2.27）、半胱天冬酶-1（0.57 对 2.68）、p20（1.67 对 3.33）和 IL-1β（1.44 对 2.41）的蛋白表达，降低了-IKB-α/IKB-α 的比值（0.47 对 2.19）。
JLD 对 NAFLD 具有保护作用，这可能与其抗细胞焦亡有关，提示 JLD 有可能成为治疗 NAFLD 的新型药物。
